GBIM:OTCMKTS
GlobeImmune Inc
0,00010 USD
0,00%
(0,00) 1 D
29. sep., 15:48:52 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GBIM …
Markedsverdi
580,00
Snittvolum
1,74k
Volum
0,00
52 u høy
0,04 USD
52 u lav
0,00 USD
Utestående aksjer
5,75 mill.
Antall ansatte
22
Markedsverdi
580,00
Snittvolum
1,74k
Volum
0,00
52 u høy
0,04 USD
52 u lav
0,00 USD
Utestående aksjer
5,75 mill.
Antall ansatte
22
Nyhetssaker
Fra nettkilder og nyhetspartnere
Vietnam.vn
·
for 12 timer siden
Hurtiglesning 15-10: S&P 500 opplever det største fallet siden juli etter inflasjonsdata, PV GAS' 9-månedersresultat nesten dobler årsmålet.
Stock Titan
·
for 1 time siden
An energy-efficiency platform's co-founder becomes a director; its CEO joins TROOPS as COO.
bloomingbit
·
for 6 minutter siden
Nasdaq-Listed Tron Files $200 Million Stock Offering to Fund TRX Purchases
Central Oregon Daily
·
for 18 minutter siden
Nasdaq slides to near one-month low as AI rout deepens
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Om GlobeImmune Inc
Administrerende direktør-
Ansatte22
Grunnlagt1. jan. 1995
HovedkontorLouisville, Colorado, USA
Sektor-
Nettstedglobeimmune.com